Here are the Form 4 insider transactions from Mentari Therapeutics, Inc. (MTRI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MTRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MTRI filings page.
InMed Pharmaceuticals Inc. (INM) officer Jerad G. Seurer, General Counsel and Corporate Secretary, received an award of options covering 257,000 common shares on November 9, 2026, at a $16 per-share exercise price. The options vest 25% on November 9, 2027, then in equal monthly installments through November 9, 2030, subject to his continued service on each vesting date, and expire November 9, 2036.
InMed Pharmaceuticals Inc. director Laura Lee Sandler received a stock-option award on November 9, 2026, representing the right to purchase 37,000 common shares at an exercise price of $16 per share. The options vest in equal monthly installments through November 9, 2029, subject to her continued service on each vesting date.
InMed Pharmaceuticals Inc. reported that Senior Vice President, Finance and Chief Accounting Officer Brett R. Hagen received an award of options covering 171,000 common shares. The options vest 25% on November 9, 2027, with the remainder vesting in equal monthly installments through November 9, 2030, subject to his continued service on each vesting date.
InMed Pharmaceuticals Inc. (INM) reported that President and Chief Executive Officer Gregory J. Divis, who is also a director, received a stock-option award representing the right to purchase 1,560,599 common shares on November 9, 2026. The options vest 25% on November 9, 2027, then in equal monthly installments through November 9, 2030, subject to his continued service on each vesting date.
InMed Pharmaceuticals Inc. director Julianne Bruno was granted options covering 37,000 common shares on November 9, 2026, at an exercise price of $16 per share. The options vest in equal monthly installments through November 9, 2029, subject to her continued service on each vesting date, and expire November 9, 2036.
InMed Pharmaceuticals Inc. reported a direct stock-option award to director Michelle Patricia Pernice: 37,000 options on November 9, 2026. Each option represents the right to purchase one common share at an exercise price of $16 per share. The options expire November 9, 2036, and her reported position following the award was 37,000 options.
InMed Pharmaceuticals Inc. (INM) director Todd Shegog received an option award on November 9, 2026, covering the right to purchase 37,000 common shares at an exercise price of $16 per share. The options vest in equal monthly installments through November 9, 2029, subject to his continued service on each vesting date, and expire November 9, 2036.